Bharat Immunologicals & Biologicals Corporation Limited announced earnings results for the third quarter ended December 31, 2019. For the third quarter, the company announced total revenue was INR 289.551 million compared to INR 83.844 million a year ago. Net loss was INR 23.502 million compared to net income of INR 183,000 a year ago. Basic loss per share was INR 0.54. Basic loss per share from continuing operations was INR 0.54. For the nine months, total revenue was INR 460.754 million. Net loss was INR 139.760 million. Basic loss per share was INR 3.21.